Kyntra Bio (NASDAQ:KYNB – Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI – Get Free Report) are both small-cap manufacturing companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.
Volatility & Risk
Kyntra Bio has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Petros Pharmaceuticals has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500.
Valuation and Earnings
This table compares Kyntra Bio and Petros Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyntra Bio | $6.44 million | 4.42 | $183.45 million | $40.46 | 0.17 |
| Petros Pharmaceuticals | $5.11 million | 0.02 | -$8.16 million | ($1.64) | -0.00 |
Kyntra Bio has higher revenue and earnings than Petros Pharmaceuticals. Petros Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations and price targets for Kyntra Bio and Petros Pharmaceuticals, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyntra Bio | 1 | 1 | 2 | 1 | 2.60 |
| Petros Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
Kyntra Bio presently has a consensus target price of $32.50, suggesting a potential upside of 362.30%. Given Kyntra Bio’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Kyntra Bio is more favorable than Petros Pharmaceuticals.
Profitability
This table compares Kyntra Bio and Petros Pharmaceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyntra Bio | 2,199.13% | N/A | -36.71% |
| Petros Pharmaceuticals | N/A | -78.22% | -23.50% |
Insider and Institutional Ownership
72.7% of Kyntra Bio shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 4.2% of Kyntra Bio shares are held by insiders. Comparatively, 12.2% of Petros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
Kyntra Bio beats Petros Pharmaceuticals on 12 of the 15 factors compared between the two stocks.
About Kyntra Bio
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
About Petros Pharmaceuticals
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.
Receive News & Ratings for Kyntra Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyntra Bio and related companies with MarketBeat.com's FREE daily email newsletter.
